Humanized antibodies against CD269 (BCMA)
AssigneeMax-DelbrüCk-Centrum FüR Molekulare Medizin In Der Helmholtz-Gemeinschaft
InventorsFelix Oden, Stephen Marino, Oliver Daumke
Life of this patent
Estimating the term…
Abstract
A method of treating a medical disorder associated with the presence of pathogenic B cells expressing B cell maturation antigen (BCMA), the method comprising administering to a subject an isolated antibody or antibody fragment comprising specific VH and VL domain complementary determining region (CDR) sequences, wherein the antibody or fragment thereof specifically binds an epitope of the extracellular domain of CD269 (BCMA).
Claims17
A method of treating a human subject to trigger cytotoxicity in pathogenic B cells expressing B cell maturation antigen (BCMA) or pathogenic plasma cells expressing BCMA, the method comprising administering to the subject an antibody fragment comprising:
- (a) a VH domain that comprises:
- CDR1 sequence RYWIS (SEQ ID NO:
- 18) or RYWES (SEQ ID NO. 19);
- CDR2 sequence EINPNSSTINYAPSLKDK (SEQ ID NO:
- 20) or EINPSSSTINYAPSLKDK (SEQ ID NO:
- 21);
- and
- CDR3 sequence SLYYDYGDAYDYW (SEQ ID NO. 22);
- and
- (b) a VL domain that comprises:
- CDR1 sequence KASQSVX1X2NVA (SEQ ID NO. 23), wherein X1X2 is ES;
- CDR2 sequence SASLRFS (SEQ ID NO 24);
- and
- CDR3 sequence QQYNNYPLTFG (SEQ ID NO. 25),
- wherein said antibody or antibody fragment binds an epitope of the extracellular domain of CD269 (BCMA).
Dependencies are inferred from the claim text.